January 24, 2023
Eisai and Biogen rolled out Leqembi (lecanemab), their new disease-modifying therapy for Alzheimer’s, in the US on January 18. The FDA granted accelerated approval for the drug on January 6 for the treatment of mild cognitive impairment (MCI) or mild...read more